Judson F N
Sex Transm Dis. 1986 Jul-Sep;13(3 Suppl):199-202. doi: 10.1097/00007435-198607000-00021.
Of the currently recommended regimens for treatment of uncomplicated gonorrhea, only aqueous procaine penicillin G is effective against infections of all sites. However, this agent is not effective against penicillinase-producing Neisseria gonorrhoeae and suffers from poor patient acceptability owing to the 10-ml volume of injection and to allergic and toxic reactions to procaine. Ceftriaxone is a new, extended-spectrum cephalosporin with a long serum half-life and is many times more active than penicillin G against both beta-lactamase-positive and -negative strains of N. gonorrhoeae. In clinical trials ceftriaxone, in a single intramuscular dose of 125 or 250 mg, has proved as effective as any other regimen in the treatment of uncomplicated gonococcal infections of the pharynx, anorectum, cervix, and urethra. Thus, ceftriaxone (125 mg) should be considered a drug of choice for uncomplicated gonorrhea, particularly where homosexual men are treated and penicillinase-producing N. gonorrhoeae and/or chromosomally mediated resistance is prevalent.
在目前推荐的治疗无并发症淋病的方案中,只有普鲁卡因青霉素G水剂对所有部位的感染均有效。然而,该药对产青霉素酶的淋病奈瑟菌无效,且由于注射体积为10毫升以及对普鲁卡因的过敏和毒性反应,患者的接受度较差。头孢曲松是一种新型的广谱头孢菌素,血清半衰期长,对β-内酰胺酶阳性和阴性淋病奈瑟菌菌株的活性比青霉素G高许多倍。在临床试验中,单剂量肌内注射125或250毫克头孢曲松已被证明在治疗咽部、肛门直肠、宫颈和尿道的无并发症淋球菌感染方面与任何其他方案一样有效。因此,头孢曲松(125毫克)应被视为无并发症淋病的首选药物,特别是在治疗同性恋男性且产青霉素酶的淋病奈瑟菌和/或染色体介导的耐药性普遍存在的情况下。